AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Hagens Berman: Judge Denies Insulin Makers’ Motion to Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices

February 15, 2019

NEWARK, N.J.--(BUSINESS WIRE)--Feb 15, 2019--Today, a federal judge’s opinion has greenlighted a national class-action lawsuit filed against Sanofi, Novo Nordisk and Eli Lilly for their systematic overpricing of insulin and concealment of a behind-the-scenes arrangement orchestrated to hike insulin prices, according to attorneys at Hagens Berman.

Hon. Brian R. Martinotti, U.S. District Judge for the District of New Jersey, granted in part and denied in part the drug companies’ motion to dismiss the case. The opinion allows state law claims from plaintiffs – people living with diabetes who Eli Lilly, Sanofi and Novo Nordisk have forced to pay skyrocketing insulin prices – and gave attorneys representing them ability to address concerns regarding individual state representation. To the extent the court requires a patient from each state, attorneys say they can and will add clients to satisfy the court’s concerns.

Find out more about the lawsuit and sign up.

Regarding the plaintiffs’ state claims, Judge Martinotti’s opinion read, “This Court finds Plaintiffs have adequately alleged fraudulent, unfair, or unconscionable conduct.” The court also held that the plaintiffs “adequately pled an ascertainable loss.”

The lawsuit states that in recent years, Sanofi, Novo Nordisk and Eli Lilly have raised the sticker or “benchmark” prices on their drugs by more than 150 percent. Some plaintiffs now pay almost $900 dollars per month just to obtain the drugs they need, according to the firm.

Hagens Berman filed the first-of-its-kind lawsuit in 2017, detailing several accounts from patients resorting to extreme measures to survive rising insulin prices, including starving themselves to control their blood sugars, under-dosing their insulin, and taking expired insulin. The complaint also detailed how class members having intentionally allowed themselves to slip into diabetic ketoacidosis – a potentially fatal blood syndrome caused by lack of insulin in the body – so that they can obtain insulin samples from hospital emergency rooms.

Steve Berman, managing partner and co-founder of Hagens Berman, was named co-lead counsel in the case by Judge Martinotti.

“In general we are pleased with the decision because we can now bring consumer protection claims in most states,” Berman said. “This ruling also clears the way for us to begin obtaining discovery from the manufacturers and PBMs so we can shine the light on exactly what has driven insulin prices sky high.”

“This ruling blows the insulin racket wide open,” he added.

The complaint states that this once affordable drug is now out of reach for many patients due to a behind-the-scenes  quid pro quo arrangement between drug makers and pharmacy benefit managers (PBMs): “increased benchmark prices are the result of a scheme and enterprise among each defendant and several bulk drug distributors. In this scheme, the defendant drug companies set two different prices for their insulin treatments: a publicly-reported, benchmark price and a lower, real price that they offer to certain bulk drug distributors.”

Are you Affected? Sign up for the Case Now.

Attorneys are currently looking for those who purchased Lantus, Levemir, Novolog, Humalog Apidra, and/or Toujeo from the following states: Alabama, Alaska, Connecticut, Delaware, Hawaii, New Hampshire, North Carolina, North Dakota, Oklahoma, Rhode Island, South Carolina, South Dakota, Virginia, West Virginia or Wyoming. Sign up here. Did you purchase Humalog in Arkansas, Illinois, Kentucky, Mississippi, New Mexico, Oregon, Tennessee or Vermont? Sign up here. Did you purchase Novolog or Levemir in Colorado, Massachusetts, Montana, Nevada, or Washington? Sign up here. Did you purchase Lantus, Apidra or Toujeo in Louisiana, Maine, Mississippi, Tennessee or Washington? Sign up here.

Hagens Berman Sobol Shapiro LLP is a consumer-rights class-action law firm with 10 offices across the country. The firm’s tenacious drive for plaintiffs’ rights has earned it numerous national accolades, awards and titles of “Most Feared Plaintiff’s Firm,” and MVPs and Trailblazers of class-action law. More about the law firm and its successes can be found at www.hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190215005526/en/

CONTACT: Ashley Klann

ashleyk@hbsslaw.com

206-268-9363

KEYWORD: UNITED STATES NORTH AMERICA ALABAMA ALASKA ARKANSAS COLORADO CONNECTICUT DELAWARE HAWAII ILLINOIS KENTUCKY LOUISIANA MAINE MASSACHUSETTS MISSISSIPPI MONTANA NEVADA NEW HAMPSHIRE NEW JERSEY NEW MEXICO NORTH CAROLINA NORTH DAKOTA OKLAHOMA OREGON RHODE ISLAND SOUTH CAROLINA SOUTH DAKOTA TENNESSEE VERMONT VIRGINIA WASHINGTON WEST VIRGINIA WYOMING

INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL

SOURCE: Hagens Berman Sobol Shapiro LLP

Copyright Business Wire 2019.

PUB: 02/15/2019 02:49 PM/DISC: 02/15/2019 02:49 PM

http://www.businesswire.com/news/home/20190215005526/en